246 related articles for article (PubMed ID: 15228899)
1. [In vitro activity of caspofungin against fluconazole-resistant Candida isolates from patients with HIV infection].
Ortiz de la Tabla-Ducasse V; Masiá-Canuto M; Martín-González C; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2004; 22(6):328-31. PubMed ID: 15228899
[TBL] [Abstract][Full Text] [Related]
2. Caspofungin activity against clinical isolates of fluconazole-resistant Candida.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2003 Dec; 41(12):5729-31. PubMed ID: 14662968
[TBL] [Abstract][Full Text] [Related]
3. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
4. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
González GM; Elizondo M; Ayala J
J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Arikan S; Sancak B; Hascelik G
Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.
Pfaller MA; Diekema DJ; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2003 Mar; 47(3):1068-71. PubMed ID: 12604543
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
[TBL] [Abstract][Full Text] [Related]
8. In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata.
Adams EK; Ashcraft DS; Pankey GA
Am J Med Sci; 2016 Mar; 351(3):265-70. PubMed ID: 26992255
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
[TBL] [Abstract][Full Text] [Related]
10. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
11. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.
Desnos-Ollivier M; Bretagne S; Raoux D; Hoinard D; Dromer F; Dannaoui E;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3092-8. PubMed ID: 18591282
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2008 Jan; 46(1):150-6. PubMed ID: 18032613
[TBL] [Abstract][Full Text] [Related]
14. Fungicidal efficacy of various honeys against fluconazole-resistant Candida species isolated from HIV
Shokri H; Sharifzadeh A
J Mycol Med; 2017 Jun; 27(2):159-165. PubMed ID: 28159362
[TBL] [Abstract][Full Text] [Related]
15. [Antifungal susceptibility among the isolates of yeast from the University Hospital of the Ryukyus].
Ohta C; Yamane N; Nakasone I; Onaga S; Nakamura K
Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2005; 16(2):127-33. PubMed ID: 16536058
[TBL] [Abstract][Full Text] [Related]
16. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.
Roling EE; Klepser ME; Wasson A; Lewis RE; Ernst EJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 May; 43(1):13-7. PubMed ID: 12052624
[TBL] [Abstract][Full Text] [Related]
17. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.
Oliveira ER; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; Redding SW
Antimicrob Agents Chemother; 2005 Aug; 49(8):3544-5. PubMed ID: 16048980
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of rilopirox against fluconazole-susceptible and fluconazole-resistant Candida isolates from patients with HIV infection.
Nenoff P; Taneva E; Pfeil B; Oswald U; Haustein UF
Mycoses; 1999 Apr; 42(1-2):55-60. PubMed ID: 10394849
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.
Bachmann SP; Patterson TF; López-Ribot JL
J Clin Microbiol; 2002 Jun; 40(6):2228-30. PubMed ID: 12037093
[TBL] [Abstract][Full Text] [Related]
20. VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.
Break TJ; Desai JV; Natarajan M; Ferre EMN; Henderson C; Zelazny AM; Siebenlist U; Hoekstra WJ; Schotzinger RJ; Garvey EP; Lionakis MS
J Antimicrob Chemother; 2018 Jan; 73(1):151-155. PubMed ID: 29040636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
